Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma

Author： Trask Peter  

Publisher： Springer Publishing Company

ISSN： 1932-2259

Source： Journal of Cancer Survivorship, Vol.5, Iss.3, 2011-09, pp. : 255-262

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma

By Tai Cheng-Jeng  

Acta Oncologica, Vol. 48, Iss. 6, 2009-08 ,pp. : 931-932

Informa Healthcare

Access to resources Recommend Favorite

Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study

By Shinsako Keiko   Mizuno Tomoyuki   Terada Tomohiro   Watanabe Jun   Kamba Tomomi   Nakamura Eijiro   Ogawa Osamu   Inui Ken-ichi  

International Journal of Clinical Oncology, Vol. 15, Iss. 5, 2010-10 ,pp. : 512-514

Springer Publishing Company

Access to resources Recommend Favorite

Flotillin-1 expression in human clear-cell renal cell carcinoma is associated with cancer progression and poor patient survival

By            

Molecular Medicine Reports, Vol. 10, Iss. 2, 2014-01 ,pp. : 860-866

Spandidos Publications

Access to resources Recommend Favorite

Reversible encephalopathy syndrome secondary to sunitinib for metastatic renal cell carcinoma patient

By Medioni Jacques   Cojocarasu Oana   Banu Eugeniu   Cassar-Queudeville Alexia   Halimi Philippe   Oudard Stéphane  

Targeted Oncology, Vol. 2, Iss. 3, 2007-07 ,pp. : 193-195

Springer Publishing Company

Access to resources Recommend Favorite

Sunitinib for metastatic renal cell carcinoma

By Mukherji Deborah   Larkin James   Pickering Lisa  

Future Oncology, Vol. 6, Iss. 9, 2010-09 ,pp. : 1377-1385

Future Medicine

Access to resources Recommend Favorite